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Objectives
The aim of this study was to evaluate the HIV-1 RNA pooled nucleic acid amplification testing
(NAAT) strategy to screen pregnant women in the ‘window period’ of acute HIV infection (AHI) in
rural South Africa.
Methods
In 2007 and 2008, 750 consecutive pregnant women on their first antenatal care visit to a primary
health care clinic were tested anonymously for HIV infection. HIV-1 RNA pooled NAAT was
performed on HIV antibody-negative samples. All positive pools were tested individually and
positive samples were classified as incident cases to calculate HIV incidence.
Results
The overall HIV prevalence was 37.3% [95% confidence interval (CI) 34.3–41.3]. Of the 467 HIV
antibody-negative samples, four (0.9%) were HIV-1 RNA-positive. The mean viral load in the four
samples was 386 260 HIV-1 RNA copies/mL (range 64 200–1 228130). The HIV incidence was 11.2%
per year (95% CI 0.3–22.1) and all women with AHI were  21 years of age.
Conclusions
Identifying AHI in pregnancy is important for health interventions to reduce perinatal and
heterosexual transmission of HIV, and to estimate HIV incidence for epidemiological surveillance.
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Introduction
Epidemiological screening for HIV infection using standard
antibody tests is crucial to understand and monitor the
spread of HIV and to provide care and treatment for those
who are infected [1]. In countries with generalized
epidemics where heterosexual transmission is dominant,
HIV seroprevalence surveys among pregnant women are
frequently used. These surveys identify individuals with
latent or advanced HIV disease and miss individuals with
‘window-period’ acute HIV infection (AHI), who are more
likely to transmit HIV due to high viral concentrations in
the blood and genital tract [2,3]. Sensitive, validated and
well-calibrated assays for HIV-1 RNA and p24 antigen, and
the fourth-generation assays for the simultaneous detec-
tion of HIV antibodies and p24 antigen, have been used
with increasing frequency to diagnose AHI [4–8]. These
tests have been used in cross-sectional studies to estimate
HIV incidence [5,6] and are useful to understand HIV
transmission dynamics and assess the impact of public
health interventions [9]. The objective of this study was to
evaluate the HIV-1 RNA pooled nucleic acid amplification
testing (NAAT) strategy to screen pregnant women for
‘window-period’ AHI and estimate HIV incidence.
Methods
Study setting and population
The study population comprised pregnant women attend-
ing seven public sector primary health care clinics in
Vulindlela, a rural community about 150 km west of
Correspondence: Dr Ayesha BM Kharsany, Centre for the AIDS Programme
of Research in South Africa (CAPRISA), Doris Duke Medical Research
Institute, Nelson R Mandela School of Medicine, University of KwaZulu-
Natal, Private Bag 7, Congella 4013, Durban, South Africa.
Tel: 1 27 31 260 4558; fax: 1 27 31 260 4566; e-mail: kharsany@ukzn.ac.za
DOI: 10.1111/j.1468-1293.2010.00838.x
r 2010 British HIV Association HIV Medicine (2010), 11, 661–665
661
Durban in the KwaZulu-Natal Midlands. As part of the
prevention of mother-to-child transmission of HIV infec-
tion, all pregnant women at these clinics are offered
voluntary HIV counselling and testing services and, if
infected, have access to programmes designed to prevent
mother-to-child transmission of HIV and antiretroviral
therapy (ART) if they meet the eligibility criteria for
initiation of treatment.
Data and sample collection
This study was undertaken as part of the annual, cross-
sectional surveys conducted from 1 October to 30
November in 2007 and 2008. This survey coincided with
the South African Department of Health’s National
Antenatal Sentinel HIV and Syphilis Prevalence Surveys
conducted annually among pregnant women, and blood
samples are tested using a single enzyme-linked immuno-
sorbent assay (ELISA) (Abbott Axsym System for HIV-1/
HIV-2; Abbott Laboratories, Chicago, IL, USA) [10]. We
included consecutive pregnant women who presented for
their first antenatal care visit at one of the seven primary
health care clinics, regardless of age. Screening for HIV
infection was anonymous and in compliance with the
World Health Organization guidelines for using HIV-testing
technologies in surveillance [1]. Trained nurses collected
two venous blood samples in prelabelled ethylenediami-
netetraacetic acid (EDTA) and plain tubes. The age of the
woman, her current partner’s age, if this was her first
pregnancy, and dates of prior pregnancies were recorded
on a standardized case report form labelled with a unique
participant identification number. Samples were trans-
ported to the central laboratory in Durban for testing.
HIV testing procedure
HIV antibody testing on serum samples was carried out
using Enzygnost* Anti-HIV-1/2 Plus (Dade Behring,
Marburg, Germany), an ELISA for the detection of
antibodies to HIV-1, HIV-2 and HIV-1 (subtype O) antigens.
Plasma from all ELISA-negative samples were batched and
tested using the pooled NAAT strategy [5,6]. Each master
pool comprised 10 samples, consisting of 100 mL from each
sample to a total volume of 1000 mL, and tested with
qualitative HIV-1 RNA polymerase chain reaction (PCR)
assay (COBAS Amplicort System, Roche Molecular Sys-
tems; Systems, Inc., Branchburg, New Jersey, USA). Master
pools testing negative were considered HIV-negative with
no further testing. If any of the master pools tested positive
for HIV-1 RNA, quantitative testing was performed on
individual samples using the COBAS AmpliPrep/COBAS
TaqMan (Roche Molecular Systems) which has a detection
level of  40 HIV-1 RNA copies/mL. HIV antibody-
negative samples with detectable plasma HIV-1 RNA were
retested using the third-generation Abbott Determine HIV-
1/2 rapid antibody test (Abbott Laboratories). We calcu-
lated the cost of HIV-1 RNA testing by including the cost of
consumables, test kits and technicians’ time.
Analysis
AHI was defined as HIV ELISA antibody-negative, quali-
tative HIV-1 RNA-positive with measurable HIV-1 RNA
copies/mL. The proportion of women with AHI was
calculated by dividing the number of women who were
HIV-1 RNA-positive by the total number of ELISA-negative
samples tested. The annual HIV incidence was calculated
using the formula I5 (365/w)Ninc/(number at risk), where I
is the incidence rate and w is the mean window of detection
(28 days). Ninc is the number of women found to be HIV-1
RNA-positive. The denominator, number at risk, is the
number of HIV ELISA seronegative women tested. The HIV
incidence is reported as a percentage per year. The 95%
confidence interval (CI) for the incidence estimate was
calculated using  1.96 I/( ﬃﬃﬃﬃNp inc) [5,6].
Ethics approval
The Biomedical Research Ethics Committee of the Uni-
versity of KwaZulu-Natal and the uMgungundlovu District
KwaZulu-Natal Department of Health approved the study.
Results
A total of 750 consecutive samples were collected from
pregnant women during their first antenatal care visit. The
HIV prevalence at screening, patient demographics and
HIV test characteristics are shown in Table 1. The overall
HIV prevalence was 37.3% (95% CI 34.3–41.3]. Of the 467
ELISA HIV antibody-negative samples, four (0.9%) tested
HIV-1 RNA-positive and antibody-negative with the
Abbott Determine rapid assay. The mean viral load was
386 260 copies/mL (range 64 200–1 228130). Based on the
HIV-1 RNA-positive samples, the point estimate of HIV
incidence was 11.2% per year (95% CI 0.3–22.1). All
women diagnosed with AHI were  21 years of age. The
ages of the current partner for two women wereo25 years
and, for the other two, 425 years. Only one woman
reported a history of a previous pregnancy. The mean ages
of women without AHI and their current partner were 22.3
years (SD 6.8, range 12–45) and 25.2 years (SD 7.9, range
16–56), respectively; 185 of 463 women reported having
had at least one previous pregnancy.
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Four of the 47 master pools testing positive with the
qualitative HIV-1 RNA assay required 40 individual
samples to be tested. A total of 87 tests were performed
(47 master pools and 40 individual tests) at a cost of 483
South African rand (R483; approximately US$61, d40) per
test, making, in total, R42 021.00 (US$5253, d3502). The
cost per individual HIV-negative sample was R90.00
(US$11, d8), while the cost of identifying a single case of
AHI was R10 505.00 (US$1313, d876).
Discussion
In this study using the HIV-1 RNA pooled NAAT strategy,
we identified 0.9% of pregnant women with AHI in the
absence of HIV antibodies. During the early years of the
HIV epidemic, among mother–infant pairs attending
immunization clinics in rural KwaZulu-Natal, 2% of
women were diagnosed with acute incident HIV infections
[4]. Our study reaffirms that a high proportion of pregnant
women with HIV infection are unlikely to be diagnosed,
and the potential for vertical and heterosexual transmis-
sion predicted by the magnitude of the viral load [2,3]
during the acute stage of infection has important public
health implications.
The HIV incidence of 11.2% per year in this study is
similar to the 10.7 per 100 person-years obtained following
retesting of HIV-negative pregnant women around the time
of delivery from urban and rural facilities in South Africa
[11]. While measuring HIV incidence by the traditional
follow-up of cohorts of HIV-uninfected individuals re-
mains the gold standard, these studies are usually time-
consuming, expensive and potentially biased by poor
retention rates. From such studies, HIV incidence rates
among 18–25-year-old nonpregnant women in Hlabisa
and Durban, South Africa, were 8.9 and 8.5 per 100 person-
years, respectively [12], indicative of the unrelentingly
high HIV incidence rates in young women in this region.
To estimate HIV incidence from cross-sectional studies,
antibody-based sensitive/less sensitive testing [13] and the
HIV-1 subtypes B, E, and D immunoglobulin G capture
enzyme immunoassay (BED-CEIA) [14] have been used.
Using BED-CEIA, data from population-based household
surveys in South Africa have shown the HIV incidence to
be 5.6% among women aged 20–29 years, compared with
0.9% in men of the same age group. Among women with a
current pregnancy, the HIV incidence was 5.2% (95% CI
0.0–12.9) [14]. A key disadvantage of the BED-CEIA is that
it is known to misclassify early or AHI with established
long-term infections and individuals on ART [5]. In the
absence of HIV antibodies, the measurement of HIV-1 RNA
and p24 antigen are both highly sensitive and specific, with
HIV-1 RNA having an added advantage of being detected
much earlier than p24 antigen [5,6]. A further advance in
diagnosing AHI has been the development of fourth-
generation HIV-1 assays, detecting p24 antigen and HIV
antibody simultaneously [8]. However, the detection levels
of these assays differ as key viral and serological markers
evolve in AHI.
Screening for epidemiological purposes has typically
described the prevalence of established infections, limiting
the understanding of ongoing transmission dynamics. HIV
prevalence from anonymous testing of pregnant women and
from nationally representative population-based household
surveys remains the mainstay of HIV surveillance [10,15].
Table 1 HIV prevalence, incidence and test characteristics among pregnant women with acute HIV infection (patients 1–4)
Characteristics Overall sample
Sample size n5 750
HIV prevalence 37.3% (95% CI 34.3–41.3)
HIV antibody-negative samples tested n5 467
HIV incidence 11.2% per year (95% CI 0.3–22.1)
Patient 1 Patient 2 Patient 3 Patient 4
Patient demographics
Age (years) 18 21 19 18
Partner’s age (years) 23 25 21 28
Number of prior pregnancies 0 1 0 0
Year of prior pregnancy NA 2004 NA NA
HIV test characteristics
ELISA* Negative Negative Negative Negative
Abbott Determine HIV-1/2 rapid test Negative Negative Negative Negative
HIV-1 RNA Positive Positive Positive Positive
Viral load (HIV-1 RNA copies/mL) 64 200 1 228 130 94 258 158 453
*Including repeat ELISA with Enzygnost* Anti-HIV-1/2 Plus.
CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; NA, not applicable.
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With increasing access to and uptake of ART, survival time
of those infected increases and the proportion with
established infections increases over time, influencing the
usefulness of HIV prevalence data for surveillance.
Dissecting the relationship between prevalence and in-
cidence becomes more complex as approaches to the
epidemic become more advanced and widely available.
Measuring HIV incidence provides a more sensitive way
of monitoring trends in HIV infection and behaviour.
Enhancing current screening programmes to include
tests for HIV-1 RNA and p24 antigen or the newer
fourth-generation HIV-1 assays to monitor AHI and HIV
incidence would provide a nuanced, sophisticated under-
standing of the epidemic, allowing more focused pre-
vention and treatment efforts to be implemented and
evaluated [8].
While the cost of identifying a single case of AHI may be
excessive at the individual level, evidence for enhanced
spread during this stage of infection and the importance for
broader public health benefit at the population level
support the need to detect AHI to prevent secondary
spread. As this was an anonymous survey, we were unable
to refer women diagnosed with AHI for care and support.
We also believe that the HIV-1 RNA pooled NAAT strategy,
rather than the BED-CEIA, should be incorporated into the
Department of Health’s annual anonymous National
Antenatal Sentinel HIV and Syphilis Prevalence Surveys
[10] to provide a parallel measure of incident HIV
infections as ART is scaled up [9].
There are several limitations to our study. It is difficult to
extrapolate our data to the general population because of
the small sample size; because the survey population
comprised pregnant women seeking antenatal care; and
because rates of new HIV infections are likely to be
different during pregnancy [16]. However, the population
represented is that of young, sexually active women, most
affected by the virus [14]. The HIV-1 RNA pooled NAAT
strategy is technically demanding, requiring laboratory
expertise; has cost implications; may fail to detect or
under-amplify some non-B subtypes; has lower specificity,
as detectable low viral load is classified as positive; and has
some loss of sensitivity due to the testing of pooled samples
[6,8]. Since the ELISA was not repeated for all the samples,
HIV antibody-negative samples could have been misclassi-
fied as false-positive. Regardless of misclassification, the
viral loads in the AHI individuals were all higher than
3000 copies/mL and unlikely to represent false-positive
results [7,8]. Nevertheless, the HIV-1 RNA pooled NAAT
strategy has been used with great efficiency to diagnose
AHI in pregnant women [17] and in high-risk individuals
from populations with low [18] and high HIV incidence
[19,20].
Diagnosing pregnant women with AHI is critical to
reducing perinatal and heterosexual transmission of HIV,
underscoring the need for vigilant and rigorous testing for
HIV infection at antenatal care visits. For epidemiological
surveillance, estimating HIV incidence is central to HIV
prevention and understanding of transmission dynamics in
generalized, hyperendemic HIV prevalence settings [9].
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